In May, the U.S. Food and Drug Administration (FDA) licensed the use of Remdesivir in an emergency, allowing hospitals and doctors to use it for patients hospitalized for Covid-19. Remdesivir is one of the drugs President Trump has used to treat Covid-19.

Gilead Sciences said the drug will be used for patients with Covid-19 aged 12 and over and hospitalized. Remdesivir became the first and only accepted drug to be used in the treatment of Covid-19, the disease that infected more than 41.9 million people globally and caused more than 1.1 million deaths.

"Since the start of the Covid-19 outbreak, Gilead has been working relentlessly to find solutions to this global health crisis," Gilead CEO Daniel O’Day said in a statement.

According to Gilead, Remdesivir is approved for temporary use as a Covid-19 treatment in approximately 50 countries worldwide. The drug Remdesivir should be used only in a hospital or in a medical facility capable of providing care equivalent to inpatient treatment in a hospital.

In early October, a study coordinated by the World Health Organization (WHO) found that the drug Remdesivir "has little or no effect" on mortality in hospitalized patients due to Covid-19.

Earlier this year, Dr Anthony Fauci, a leading expert on infectious diseases, said Gilead’s drug Remdesivir would become the "new standard of care" for patients treated with Covid-19.

According to CNBC, most patients treated with Remdesivir will receive a 5-day course. The drug is currently used intravenously, but the company is working on developing a form of the drug used in the respiratory tract. The company Gilead said that the drug Remdesivir is not taken in tablet form because its composition will affect the liver.

Remdesivir, which will be sold under the name Veklury, costs $2,340 with a five-day treatment for government agencies or $3,120 for American patients with private health insurance.

In August, gilead announced plans to produce more than 2 million doses of Remdesivir by the end of 2020 and is expected to produce "several million more doses" by 2021. At the same time, the production network of this drug has also expanded to more than 40 companies in North America, Europe and Asia.

Gilead said on October 22 that it is meeting the demand for the drug in the U.S. and is expected to meet global demand this October.